Porvair Sciences to improve the diagnosis and treatment of ovarian cancer

Porvair Sciences reports on its involvement in a new £2.6 million project led by Swansea University (UK) that aims to dramatically improve the diagnosis and treatment of ovarian cancer.

This project will involve collaboration with 5 key industrial partners - Porvair Sciences, Bruker UK, GE Healthcare UK, Axis Bio and GlaxoSmithKline (GSK). A new Antibody Drug Conjugates company will join the project in its second year.

Antibody Drug Conjugates (ADC’s) are a powerful new class of therapeutics in medical oncology, where antibodies that target specific cancers are coupled with cytotoxic agents.

The Cluster for Epigenomic and Antibody-Drug Conjugate Therapeutics (CEAT) project aims to utilize novel epigenetic drugs and ADC’s to manipulate chemical compounds thus creating a new route for the treatment of ovarian cancer.

Utilizing its proprietary Chromatrap® bead-free Chromatin Immunoprecipitation (ChIP) technology - Porvair Sciences will develop new epigenomic profiling approaches that will deliver the required advances in cutting-edge drug development and patient profiling.

Using the Chromatrap® technology, Porvair Sciences will work with Swansea University and industrial partners to identify and characterize epigenetic drugs that are effective in preventing cancer development in ovarian cancer models. In addition, Porvair Sciences will support the evaluation of the Antibody Drug Conjugates (ADCs) resulting from the CEAT project.

Epigenetics involves chemical changes to the DNA and associated proteins that can lead to genes being turned on or off. In some cases, this can go wrong and lead to disease. Through the CEAT project, Swansea University will work closely with CEAT partners to develop drugs that can control epigenetic signals; these epigenetic drugs can be targeted specifically towards ovarian cancer cells where epigenetic changes have occurred.”

Dr. Lewis Francis, Principal Investigator

We are delighted to be involved with the CEAT project. This is a great opportunity for the project to leverage our bead-free ChIP technology and expertise to be at the forefront of developing epigenetic-based cancer therapies”

Amy Johnson, Porvair Sciences

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Chromatrap® - Porvair Sciences Ltd. (2019, June 24). Porvair Sciences to improve the diagnosis and treatment of ovarian cancer. News-Medical. Retrieved on June 22, 2024 from https://www.news-medical.net/news/20190227/Porvair-Sciences-involves-in-new-project-to-improve-diagnosis-treatment-of-ovarian-cancer.aspx.

  • MLA

    Chromatrap® - Porvair Sciences Ltd. "Porvair Sciences to improve the diagnosis and treatment of ovarian cancer". News-Medical. 22 June 2024. <https://www.news-medical.net/news/20190227/Porvair-Sciences-involves-in-new-project-to-improve-diagnosis-treatment-of-ovarian-cancer.aspx>.

  • Chicago

    Chromatrap® - Porvair Sciences Ltd. "Porvair Sciences to improve the diagnosis and treatment of ovarian cancer". News-Medical. https://www.news-medical.net/news/20190227/Porvair-Sciences-involves-in-new-project-to-improve-diagnosis-treatment-of-ovarian-cancer.aspx. (accessed June 22, 2024).

  • Harvard

    Chromatrap® - Porvair Sciences Ltd. 2019. Porvair Sciences to improve the diagnosis and treatment of ovarian cancer. News-Medical, viewed 22 June 2024, https://www.news-medical.net/news/20190227/Porvair-Sciences-involves-in-new-project-to-improve-diagnosis-treatment-of-ovarian-cancer.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
High recovery of top-quality purified RNA